Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Medical Minute on Key Decisions in HIV Care: Treating HIV/HCV Coinfection

In this case example, learn the data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.
Mark S. Sulkowski, MD
Released: January 19, 2022

Information on this Educational Activity

Faculty

Mark S. Sulkowski, MD

Professor of Medicine
Medical Director,
Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received funds for research support from AbbVie, Assembly Bio, Gilead Sciences, and Janssen and consulting fees from AbbVie, Antios, Arbutus, Assembly Bio, Gilead Sciences, ViiV, and Virion.

Program Medium

This program has been made available online.

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Dr Yan Zhao discusses data from IDWeek 2022 on long-term benefits of early vs delayed treatment initiation in people with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 22, 2022

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings